Cancer du sein : la moitié des femmes atteintes pourraient recevoir un nouveau traitement "majeur"

A treatment currently used for metastatic breast cancers may actually be effective in many more women with breast cancer, according to a new study presented at the Chicago Cancer Congress.

the breast cancer treatment will he be revolutionized by this discovery? According to a new international study presented this Sunday at the Chicago Cancer Congress (ASCO) and published in the New England Journal of Medicinethe anti-HER2 therapy currently used in women with metastatic breast cancer may actually be effective in more women.

In women with metastatic breast cancer (2,000 to 3,000 in total in France), the tumor presents a protein – the HER2 protein – in very large quantities. The researchers then wanted to know if this anti-HER2 treatment could also be effective in patients who also present this protein, but in a lower quantity.

In total, the study counted 557 patients with HER2-low metastatic breast cancer (i.e. low protein expression). They were randomly assigned to two groups: one received trastuzumab deruxtecan and the other chemotherapy chosen by the doctor. “In the hormone receptor positive cohort, median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician’s choice group and overall survival was 23.9 months and 17. 5 months, respectively“, indicates the study.

5,000 additional women will benefit from the treatment

Either a gain of 6 months of life with the new treatment, for women who are given five years of life expectancy. “The results are significant. These patients lived six months longer on average. It may not seem like much, but it really took a leap forward that we hadn’t seen in more than fifteen years in this subtype of disease”he told France Info.

This new treatment could be expanded and more than 5,000 women with breast cancer will be able to benefit from it – and perhaps even more in the future. “It’s a huge message of hope because when you have this kind of demonstration at advanced stages of the disease, the next step is going to be to try to do it at increasingly earlier stages. And to arrive at localized stages to no longer increase the quantity of life, but the healing rates so that more patients can heal at the end. And that is major, because globally it represents half of the women who have breast cancer.“, enthuses the researcher.

For all women affected, this therapy could also help to reduce chemotherapytoxic and sometimes poorly tolerated by women.

Source :

  • Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, The New England Journal of MedicineJune 5, 2022

Read also:

Subscribe to the Top Santé Newsletter to receive the latest news for free

#Breast #cancer #women #affected #receive #major #treatment

Leave a Reply

Your email address will not be published.